Myfortic
PreclinicalSmall molecule
NovartisMyfortic is one of 65 small molecule programs targeting Transplant Recipient. It is currently in Preclinical.
3
Indications
23
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Lupus Nephritis
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Medrol
PfizerApproved
Rituxan
RocheApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Farxiga
AstraZenecaApproved
Myfortic
NovartisApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Imuran
LLegacy Health System
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Kerendia
BayerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver Transplant6 trials
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
Enrolling by invitation·—·Phase 4·NCT02081755·336 enrolled
Kidney Transplant3 trials
Renal Transplant2 trials
Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)
Unknown status·—·Phase 4·NCT00676221·110 enrolled
Transplant Recipient1 trial
10 more indications
Heart Transplant1 trial
Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms
Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 3·NCT00468936·100 enrolled
Cardiovascular1 trial
Fibrosis1 trial
Renal Transplant Recipients1 trial
Tacrolimus1 trial
Ischemia Reperfusion Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Myfortic. EMBL-EBI & Wellcome Sanger Institute.
- [4]